Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

Rhea-AI Summary

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs) for cancer treatment, announced plans to report its financial results for Q4 and full year 2022 on February 28, 2023. The company will host a conference call at 8:00 a.m. ET, accessible via domestic and international dial-in numbers. Mersana is developing multiple ADCs, including UpRi, which targets platinum-resistant ovarian cancer and is currently in several clinical trials. The company’s innovative ADC platforms are also in use by partners to advance their own drug pipelines.

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

To access the call, please dial 646-307-1963 (domestic) or 800-715-9871 (international) and provide the Conference ID 5417347. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi in combination with carboplatin; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

When will Mersana Therapeutics report its financial results for 2022?

Mersana Therapeutics will report its financial results for the fourth quarter and full year ended December 31, 2022, on February 28, 2023.

What time is the Mersana Therapeutics conference call?

The conference call for Mersana Therapeutics will take place at 8:00 a.m. Eastern Time on February 28, 2023.

How can I access the Mersana Therapeutics conference call?

To access the Mersana Therapeutics conference call, dial 646-307-1963 domestically or 800-715-9871 internationally and provide Conference ID 5417347.

What is Mersana's lead product candidate?

Mersana's lead product candidate is upifitamab rilsodotin (UpRi), designed to target NaPi2b in patients with ovarian cancer.

What trials is Mersana conducting with UpRi?

Mersana is conducting several trials, including UPLIFT, UPGRADE-A, and UP-NEXT, to evaluate UpRi in different treatment scenarios for ovarian cancer.